Mangiferin attenuates Ang II-induced abdominal aortic aneurysm by blocking Lys591-mediated nuclear translocation of...

Abdominal aortic aneurysm (AAA) is a lethal vascular disorder characterized by aortic dilation and medial degeneration, with no effective pharmacological interventions currently available. Pathological vascular smooth muscle cell (VSMC) phenotypic switching and apoptosis drive AAA progression. Mangiferin, a bioactive xanthone from Mangiferia indica l., exhibits anti-inflammatory and cardiovascular protective properties that could potentially alleviate AAA.

This study aims to investigate mangiferin's therapeutic effects on AAA and elucidate its molecular mechanisms.

Apolipoprotein E-deficient (ApoE^-/-) mice were infused with angiotensin II (Ang II) to induce AAA and subsequently treated with low-dose (10 mg/kg/d) or high-dose (50 mg/kg/d) mangiferin. Aortic pathology was assessed via histological analysis, zymography, and immunofluorescence. VSMC phenotypic switching and apoptosis were examined through western blotting and immunofluorescence, while their molecular regulation by mangiferin was investigated using a combined approach of RNA-sequencing, molecular docking, cellular thermal shift assay, and functional studies.

Compared to low dose-mangiferin, high dose-mangiferin reduced the incidence of AAA, aneurysm diameter enlargement, and elastin degradation in the AAA model. Mangiferin pretreatment also attenuated VSMC phenotypic switching and apoptosis in Ang II-stimulated VSMCs compared to non-pretreatment. Mechanistically, mangiferin directly bound to STAT3 at Lys591 via hydrogen bonding in the SH2 domain, inhibiting its Tyr705 phosphorylation and dimerization, and eventually blocking its nuclear translocation. This in turn suppressed KLF5 transcriptional activity and pro-aneurysmal target expression. Furthermore, both pharmacological and genetic activation of the STAT3-KLF5 axis abrogated mangiferin's protective effects in the AAA model.

This study is the first to demonstrate that mangiferin inhibits AAA by targeting the STAT3-KLF5 axis to stabilize VSMC contractility and survival, placing mangiferin as a novel natural therapeutic candidate for AAA.